Exelixis, Inc.
zanzalintinib
previously treated metastatic colorectal cancer
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for zanzalintinib in previously treated metastatic colorectal cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“We expect key data readouts from STELLAR-303 and STELLAR-304, advancing enrollment in STELLAR-311, and initiation of STELLAR-316.”